Page last updated: 2024-12-10
c 31g
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
C 31G: mixture of above cpds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3086239 |
SCHEMBL ID | 15532154 |
MeSH ID | M0115548 |
Synonyms (5)
Synonym |
---|
c-31g |
86903-77-7 |
c 31g |
SCHEMBL15532154 |
carboxymethyl-dodecyl-dimethylazanium;n,n-dimethyldodecan-1-amine oxide |
Research Excerpts
Toxicity
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Kinetic studies of absorption and disposition after oral dosing in mice with [3H]C31G were used to determine the body burden (0." | ( Mice and rabbit models for oral and percutaneous absorption and disposition of amphoteric surfactant C31G. Hahn, EC; Kenyon, AJ; Michaels, EB, 1983) | 0.27 |
" C31G, a surface active anti-infective agent that is active in vitro against bacterial and viral STD pathogens, was evaluated in a 3-day, once-daily dosing clinical trial designed to assess multiple formulations for safety and acceptance." | ( Microbicides--evaluating multiple formulations of C31G. Bax, R; Bowden, M; Douville, K; Higgins, J; McCormick, D; Rosenberg, M, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (31)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (16.13) | 18.7374 |
1990's | 9 (29.03) | 18.2507 |
2000's | 12 (38.71) | 29.6817 |
2010's | 5 (16.13) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 26.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.28) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 11 (35.48%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (64.52%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |